The dıagnostıc Value of Serum autotaxın Level ın Colorectal Cancer

NCT06091592 | Completed

• 1 other identifier: DYB-GC-AB-01
• Study Type: observational
• Target: 129
• Locations: 1 country
• Sites: 1

Brief Summary

Colorectal cancer is one of the most common causes of cancer-related death. Early diagnosis is extremely important in terms of treatment and mortality. In this study, we investigated the diagnostic value of serum autotaxin levels in colorectal cancer.

Conditions

Colo-rectal Cancer

Keywords

Colorectal cancer; autotaxın; biomarker

Outcome Measures

Primary Outcomes (1)

• Serum autotaxın level

  The value measured by the Elisa method in blood samples taken from patients and healthy volunteers.

  one years

Secondary Outcomes (3)

• Tumor location

  one years

• TNM stages

  one years

• tumor differentiation grade

  one years

Study Arms (2)

Patient ( cancer)

. The colorectal cancer patient group included clinical stage 1-3 patients of both sexes. Patients with metastatic disease, those who received neoadjuvant therapy, those who received systemic chemoradiotherapy, those who had any known systemic inflammatory or autoimmune disease, those with another concurrent malignancy, and those who had been previously diagnosed and treated for another malignancy were excluded from the study.

Other: Serum autotaxın levels

Control (healthy volunteer)

The control group included healthy volunteers who had undergone screening colonoscopy within the last month, had no pathology, had not been diagnosed with any malignant disease before, had no known systemic inflammatory or autoimmune disease, and had not been diagnosed with inflammatory bowel disease.

Other: Serum autotaxın levels

Interventions

Serum autotaxın levels OTHER

Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.

Control (healthy volunteer); Patient ( cancer)

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The colorectal cancer patient group included clinical stage 1-3 patients of both sexes. Patients with metastatic disease, those who received neoadjuvant therapy, those who received systemic chemoradiotherapy, those who had any known systemic inflammatory or autoimmune disease, those with another concurrent malignancy, and those who had been previously diagnosed and treated for another malignancy were excluded from the study. The control group included healthy volunteers who had undergone screening colonoscopy within the last month, had no pathology, had not been diagnosed with any malignant disease before, had no known systemic inflammatory or autoimmune disease, and had not been diagnosed with inflammatory bowel disease.

You may qualify if:

• stage 1-3 colorectal cancer
• control group included healthy volunteers who had undergone screening colonoscopy within the last month , had no pathology,

You may not qualify if:

• metastatic disease,
• received neoadjuvant therapy
• received systemic chemoradiotherapy
• had any known systemic inflammatory or autoimmune disease
• had a with another concurrent malignancy
• had been previously diagnosed and treated for another malignancy

Sponsors & Collaborators

• Diskapi Yildirim Beyazit Education and Research Hospital: lead

Study Sites (1)

Dışkapı Yıldırım Beyazıt training and research hospital

Ankara, 06610, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

5-10 ml of venous blood samples were taken from patients and healthy volunteers using blood collection tubes without anticoagulants.

MeSH Terms

Conditions

Colonic Neoplasms; Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Study Officials

• ismail o kaya

  Dışkapı Yıldırım Beyazıt training and research hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PROFESSOR

Study Record Dates

• First Submitted: October 14, 2023
• First Posted: October 19, 2023
• Study Start: December 30, 2020
• Primary Completion: November 20, 2021
• Study Completion: December 25, 2021
• Last Updated: October 19, 2023

Record last verified: 2023-10

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)